Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 251 participants.
Also called NCT03520972
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 251 participants
- Registry
-
NCT03520972
-
- Other papers using this trial's data
- Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03520972. Randomized; triple masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2019-07-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- PB-119 75ug
- Intervention (Drug)
- PB-119 150ug
- Intervention (Drug)
- PB-119 200ug
- Intervention (Drug)
- placebo
- Lead sponsor
- PegBio Co., Ltd.
- Collaborator
- Tigermed Consulting Co., Ltd
Record details
- Record id
cardio:ct-nct03520972- Content hash
0ee254fdab47912f384e7b0f017ca10506b0a979f898d64f71fcd5b0a3589795